Who to call at Molecular Targeting Technologies, and when
Fundz watches for the moments Molecular Targeting Technologies starts buying, and tells you who to reach.
- An alert the day Molecular Targeting Technologies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Molecular Targeting Technologies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Molecular Targeting Technologies. With Fundz connected, it knows.
Molecular Targeting Technologies, Inc. has received a $3.17M grant from the National Cancer Institute to support the development of ¹⁷⁷Lu-EBRGD for non-small cell lung cancer.
West ChesterBiotechnologyHealth CareDescription
Molecular Targeting Technologies, based in West Chester, PA, has been awarded a $3.17M five-year grant from the National Cancer Institute. The funding will advance the development of an investigational radiopharmaceutical targeting integrin αvβ3 for non-small cell lung cancer. This award will support various activities, including preclinical research and planned clinical studies. The aim is to establish a robust foundation for evaluating ¹⁷⁷Lu-EBRGD in patients.
Quick answer
Molecular Targeting Technologies, Inc. has received a $3.17M grant from the National Cancer Institute to support the development of ¹⁷⁷Lu-EBRGD for non-small cell lung cancer. (September 23, 2026). Molecular Targeting Technologies is based in West Chester, Pennsylvania, United States.
- What agreement did Molecular Targeting Technologies announce on September 23, 2026?
- Molecular Targeting Technologies, based in West Chester, PA, has been awarded a $3.17M five-year grant from the National Cancer Institute. The funding will advance the development of an investigational radiopharmaceutical targeting integrin αvβ3 for non-small cell lung cancer.
- What does Molecular Targeting Technologies do?
- Molecular Targeting Technologies, Inc. (MTTI) is a private, clinical-stage biotech company developing targeted radiopharmaceuticals (TRP) for rare cancers.
- Where is Molecular Targeting Technologies based?
- Molecular Targeting Technologies is based in West Chester, Pennsylvania, United States.
- Which similar companies announced agreements around the same time?
- IgniteData (October 15, 2026), NeOnc Technologies (October 16, 2026), Danaher (October 18, 2026) and Encare AB (October 18, 2026) also announced agreements within 45 days of Molecular Targeting Technologies.
Source: Fundz verified event record.
Other recent agreements in Biotechnology and Health Care
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- IgniteData and RealTime eClinical Solutions Partner to Enhance Clinical Data Transfer. (October 15, 2026)
- NeOnc Technologies Signs MoU with Abu Dhabi Department of Health (October 16, 2026)
- Danaher and NVIDIA Partner to Advance Autonomous Science Through AI Technology. (October 18, 2026)
- Encare AB Signs Agreement with National Cancer Institute of Thailand to Enhance Surgical Care. (October 18, 2026)
- NUCLIDIUM and NorthStar Forge Long-term Strategic Partnership to Enhance Copper-67 Radiotheranostic Oncology Pipeline. (October 19, 2026)
- Penelope Bourbon Partners with FCancer to Celebrate Fifth Anniversary with $250,000 Commitment. (October 19, 2026)
Related People
Molecular Targeting Technologies signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.